Načítá se...
Generalization of the time-to-event continual reassessment method to bivariate outcomes
This article considers the problem of designing Phase I-II clinical trials with delayed toxicity and efficacy outcomes. The proposed design is motivated by a Phase I-II study evaluating all-trans retinoic acid (ATRA) in combination with a fixed dose of daratumumab in the treatment of relapsed or ref...
Uloženo v:
| Vydáno v: | J Biopharm Stat |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6823630/ https://ncbi.nlm.nih.gov/pubmed/31264936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2019.1634087 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|